| Catalog Number |
PR172152362 |
| CAS |
172152-36-2 |
| Description |
Ilaprazole is a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. A weak base, ilaprazole accumulates in the acidic environment of the secretory canaliculus of the gastric parietal cell where it is converted to an active sulfenamide form that binds to cysteine sulfhydryl groups on the luminal aspect of the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting the pump's activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. |
| Synonyms |
noltec; Iy 81149 |
| IUPAC Name |
2-[(4-methoxy-3-methylpyridin-2-yl)methylsulfinyl]-6-pyrrol-1-yl-1H-benzimidazole |
| Molecular Weight |
366.4 |
| Molecular Formula |
C19H18N4O2S |
| InChI |
HRRXCXABAPSOCP-UHFFFAOYSA-N |
| InChI Key |
InChI=1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22) |
| Drug Categories |
Anti-Ulcer Agents; Benzimidazoles; Gastric Acid Lowering Agents; Heterocyclic Compounds, Fused-Ring; Proton Pump Inhibitors; Pyridines; Sulfoxides; Sulfur Compounds |
| Drug Interactions |
Alendronic acid-The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Ilaprazole.
Amphetamine-Ilaprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Belumosudil-The serum concentration of Belumosudil can be decreased when it is combined with Ilaprazole.
Bosutinib-The serum concentration of Ilaprazole can be decreased when it is combined with Bosutinib.
Budesonide-Ilaprazole can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Isomeric SMILES |
CC1=C(C=CN=C1CS(=O)C2=NC3=C(N2)C=C(C=C3)N4C=CC=C4)OC |
| Type |
Small Molecule |
| Therapeutic Category |
Anti-Ulcerative |
It should be noted that our service is only used for research, not for clinical use.
